Hospital readmission rates and risk factors for readmission following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies

Yael Dreznik*, Aviad Hoffman, Tamar Hamburger, Almog Ben-Yaacov, Yossi Dux, Harel Jacoby, Yaniv Berger, Aviram Nissan, Mordechai Gutman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Background: Cytoreductive surgery and Hyperthermic intra-peritoneal chemotherapy (CRS/HIPEC) for peritoneal surface malignancies is associated with high morbidity. The increased numbers of patients undergoing CRS/HIPEC in recent years mandates risk analysis and quality assurance. However, only scarce data exist regarding causative parameters for readmission. The aim of this study was to assess readmission rates and risk factors associated with readmission. Methods: A retrospective-cohort study including patients from two high-volume centers who underwent CRS/HIPEC surgery between the years 2007–2016 was performed. Patients’ demographics, peri-operative data and readmission rates were recorded. Results: 223 patients were included in the study. The 7 and 30-day readmission rates were 3.5% (n = 8) and 11% (n = 25), respectively. Late readmission rates (up to 90 days) were 11% (n = 25). The most common causes of readmission were surgical related infections (35%), small bowel obstruction (17.5%) and dehydration (14%). Post-operative complications were associated with higher readmission rates (p = 0.0001). PCI score was not associated with higher rates of readmission. Conclusion: Readmissions following CRS/HIPEC occur mainly due to infectious complications and dehydrations. Patients following CRS/HIPEC should be discharged after careful investigation to a community based continuing care with access for IV fluid replacement or antibiotics administration when required.

Original languageEnglish
Pages (from-to)278-282
Number of pages5
JournalSurgeon
Volume16
Issue number5
DOIs
StatePublished - Oct 2018

Keywords

  • CRS/HIPEC
  • Complications
  • Readmission

Fingerprint

Dive into the research topics of 'Hospital readmission rates and risk factors for readmission following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies'. Together they form a unique fingerprint.

Cite this